false
--12-31
0001651407
0001651407
2024-05-13
2024-05-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
May 13, 2024
Checkpoint
Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware |
|
001-38128 |
|
47-2568632 |
(State
or Other Jurisdiction of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer Identification No.) |
95
Sawyer Road, Suite
110
Waltham, MA 02453
(Address of Principal Executive Offices)
(781) 652-4500
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Exchange
Act:
Title
of each class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
Common Stock, par value $0.0001 per share |
CKPT |
NASDAQ Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 |
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
As described under Item 5.07 of this Current
Report, on May 13, 2024, the stockholders of Checkpoint Therapeutics, Inc., (the “Company”) voted at the Company’s
2024 annual meeting of stockholders (the “2024 Annual Meeting”) to approve an amendment to the Company’s Amended and
Restated 2015 Incentive Plan to increase the number of shares of common stock available for issuance thereunder by 12,000,000 shares
from 6,000,000 to 18,000,000 shares.
A copy of the Company’s Amended and Restated
2015 Incentive Plan is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference in this Item
5.02. A copy of the Company’s Amended and Restated 2015 Incentive Plan was filed as Appendix B to the proxy statement on Schedule
14A for the 2024 Annual Meeting filed with the Securities and Exchange Commission (the “SEC”) on April 2, 2024.
Item 5.03. |
Amendments
to Articles of Incorporation or Bylaws; Change in Fiscal Year |
As described under Item 5.07 of this Current
Report, on May 13, 2024, the stockholders of the Company voted at the 2024 Annual Meeting to approve an amendment to the Company’s
Amended and Restated Certificate of Incorporation to increase the number of shares of common stock authorized for issuance by 95,000,000
shares, bringing the total number of authorized shares of common stock to 175,000,000 shares (the “Amendment”).
On May 13, 2024, following the 2024 Annual
Meeting, the Company filed a certificate of amendment (the “Certificate”) giving effect to the Amendment with the Secretary
of State of the State of Delaware. A copy of the Certificate is filed as Exhibit 3.1 to this Current Report on Form 8-K and
is incorporated by reference in this Item 5.03. A copy of the Amendment was filed as Appendix A to the proxy statement on Schedule 14A
for the 2024 Annual Meeting filed with the SEC on April 2, 2024.
Item 5.07. |
Submission
of Matters to a Vote of Security Holders. |
On May 13, 2024, the Company held its 2024
Annual Meeting of stockholders at 10:00 a.m. Eastern Time by means of an online virtual meeting platform. There were 34,986,279
shares of common stock and 700,000 shares of Class A common stock outstanding on the record date, representing 73,471,186 votes.
Stockholders representing 58,315,283, or 79.37%, of the 73,471,186 votes outstanding were represented in person or by proxy constituting
a quorum.
At the 2024 Annual Meeting, the following proposals
were approved: (i) the election of seven directors to hold office until the 2025 annual meeting; (ii) the ratification of the
appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024;
(iii) an amendment to the Company’s Amended and Restated Certificate of Incorporation, to increase the Company’s authorized
shares of common stock by 95,000,000 shares from 80,000,000 to 175,000,000 shares; (iv) an amendment to the Company’s Amended
and Restated 2015 Incentive Plan to increase the shares of common stock available for issuance thereunder by 12,000,000 shares from 6,000,000
to 18,000,000 shares; (v) the advisory vote on the compensation of the Company’s named executive officers; and (vi) the advisory
vote of a three-year frequency for the advisory vote on the compensation of the Company’s named executive officers. These proposals
are described in detail in the Company’s definitive proxy statement on Schedule 14A for the 2024 Annual Meeting filed with the
SEC on April 2, 2024.
Proposal 1
The votes with respect to the election of seven
directors to hold office until the 2025 annual meeting were as follows:
Director | |
For | | |
% Voted For | | |
Withheld | | |
% Voted
Withheld | | |
Broker Non- Votes | |
Michael S. Weiss | |
| 46,518,929 | | |
| 96.92 | % | |
| 1,480,328 | | |
| 3.08 | % | |
| 10,316,026 | |
Christian Béchon | |
| 46,829,110 | | |
| 97.56 | % | |
| 1,170,147 | | |
| 2.44 | % | |
| 10,316,026 | |
Neil Herskowitz | |
| 45,715,861 | | |
| 95.24 | % | |
| 2,283,396 | | |
| 4.76 | % | |
| 10,316,026 | |
James F. Oliviero | |
| 46,806,020 | | |
| 97.51 | % | |
| 1,193,237 | | |
| 2.49 | % | |
| 10,316,026 | |
Lindsay A. Rosenwald, M.D. | |
| 46,527,148 | | |
| 96.93 | % | |
| 1,472,109 | | |
| 3.07 | % | |
| 10,316,026 | |
Barry Salzman | |
| 45,905,138 | | |
| 95.64 | % | |
| 2,094,119 | | |
| 4.36 | % | |
| 10,316,026 | |
Amit Sharma, M.D. | |
| 47,035,291 | | |
| 97.99 | % | |
| 963,966 | | |
| 2.01 | % | |
| 10,316,026 | |
Proposal 2
The votes with respect to the ratification of
KPMG LLP as the Company’s independent registered accounting firm for the year ending December 31, 2024 were as follows:
Total Votes For | |
Total Votes Against | |
Abstentions | |
Broker Non-Votes |
57,413,375 | |
486,058 | |
415,850 | |
- |
Proposal 3
The votes with respect to the approval of an
amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the Company’s authorized shares
of common stock by 95,000,000 shares from 80,000,000 to 175,000,000 shares were as follows:
Total Votes For | |
Total Votes Against | |
Abstentions | |
Broker Non-Votes |
51,025,382 | |
6,942,877 | |
347,024 | |
- |
Proposal 4
The votes with respect to the approval of an
amendment to the Company’s Amended and Restated 2015 Incentive Plan to increase the shares of common stock available for issuance
thereunder by 12,000,000 shares from 6,000,000 to 18,000,000 shares were as follows:
Total Votes For | |
Total Votes Against | |
Abstentions | |
Broker Non-Votes |
44,020,881 | |
3,918,197 | |
60,179 | |
10,316,026 |
Proposal 5
The votes with respect to the advisory vote to
approve the compensation of the Company’s named executive officers were as follows:
Total Votes For | |
Total Votes Against | |
Abstentions | |
Broker Non-Votes |
45,656,956 | |
2,179,041 | |
163,260 | |
10,316,026 |
Proposal 6
The votes with respect to the advisory vote on
the frequency of the advisory vote on the compensation of the Company’s named executive officers were as follows:
3 Years | |
2 Years | |
1 Year | |
Abstentions | |
Broker Non-Votes |
43,936,821 | |
129,643 | |
3,687,579 | |
245,214 | |
- |
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 14, 2024 |
Checkpoint Therapeutics, Inc. |
|
(Registrant) |
|
|
|
|
|
By |
/s/
James F. Oliviero |
|
|
James F. Oliviero |
|
|
President and Chief Executive
Officer |
Exhibit 3.1
CERTIFICATE OF AMENDMENT
OF
AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF
CHECKPOINT THERAPEUTICS, INC.
Checkpoint Therapeutics, Inc.,
a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”),
does hereby certify as follows:
FIRST: That the Corporation’s
original Certificate of Incorporation was filed on November 10, 2014.
SECOND: That the Board of Directors
of the Corporation duly adopted resolutions by written consent proposing and declaring advisable the amendment of the Amended and Restated
Certificate of Incorporation of the Corporation, as follows:
The first paragraph of ARTICLE
IV of the Amended and Restated Certificate of Incorporation be replaced and amended in its entirety to read as follows:
1. Common Stock.
The total number of shares of capital stock that the Corporation shall have the authority to issue is one hundred seventy-five million
(175,000,000) shares of Common Stock, with $0.0001 par value, of which seven hundred thousand (700,000) shares are designated as “Class A
Common Stock” (the “Class A Common Stock”). The powers, preferences
and relative participating, optional and other special rights of the respective classes of the Corporation’s capital stock or the
holders thereof and the qualifications, limitations and restrictions thereof are as follows:
THIRD: That such amendment
of the Amended and Restated Certificate of Incorporation of the Corporation was duly adopted in accordance with the provisions of Section 242
of the General Corporation Law of the State of Delaware.
IN WITNESS WHEREOF, the Corporation
has caused this Certificate of Amendment of the Amended and Restated Certificate of Incorporation to be signed by its President and Chief
Executive Officer on this 13th day of May, 2024.
|
CHECKPOINT THERAPEUTICS, INC. |
|
|
|
By: |
/s/ James F. Oliviero |
|
James F. Oliviero, President and CEO |
Exhibit 10.1
CHECKPOINT THERAPEUTICS, INC.
AMENDED AND RESTATED
2015 INCENTIVE PLAN
ARTICLE 1
PURPOSE
1.1. GENERAL.
The purpose of the Checkpoint Therapeutics, Inc. Amended and Restated 2015 Incentive Plan (the “Plan”) is to promote
the success, and enhance the value, of Checkpoint Therapeutics, Inc. (the “Company”), by linking the personal interests
of employees, officers, directors and consultants of the Company or any Affiliate (as defined below) to those of Company stockholders
and by providing such persons with an incentive for outstanding performance. The Plan is further intended to provide flexibility to the
Company in its ability to motivate, attract, and retain the services of employees, officers, directors and consultants upon whose judgment,
interest, and special effort the successful conduct of the Company’s operation is largely dependent. Accordingly, the Plan permits
the grant of incentive awards from time to time to selected employees, officers, directors and consultants of the Company and its Affiliates.
1.1 HISTORY.
The Plan was originally adopted by the Board on March 3, 2015, and was approved by the stockholders of the Company on the same date.
The Plan was amended and restated by the Board on December 18, 2015, and was approved by the stockholders of the Company on the same
date. The Plan was further amended and restated by the Board on April 10, 2017, and approved by the stockholders of the Company on
June 14, 2017. The Plan was further amended by the Board on March 3, 2020, and approved by the stockholders of the Company on
June 4, 2020. The Plan was further amended by the Board on November 3, 2022, and was approved by the stockholders of the Company
on the same date. The Plan was further amended and restated by the Board on April 5, 2023, and was approved by the stockholders of
the Company on June 12, 2023. The Plan was further amended and restated by the Board on March 21, 2024, contingent on approval
of the stockholders of the Company on May 13, 2024.
ARTICLE 2
DEFINITIONS
2.1. DEFINITIONS.
When a word or phrase appears in this Plan with the initial letter capitalized, and the word or phrase does not commence a sentence, the
word or phrase shall generally be given the meaning ascribed to it in this Section or in Section 1.1 unless a clearly different
meaning is required by the context. The following words and phrases shall have the following meanings:
(a) “Affiliate”
means (i) any Subsidiary or Parent, or (ii) an entity that directly or through one or more intermediaries controls, is controlled
by or is under common control with, the Company, as determined by the Committee.
(b) “Award”
means an award of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Deferred Stock Units, Performance Awards,
Other Stock-Based Awards, or any other right or interest relating to Stock or cash, granted to a Participant under the Plan.
(c) “Award
Certificate” means a written document, in such form as the Committee prescribes from time to time, setting forth the terms and conditions
of an Award. Award Certificates may be in the form of individual award agreements or certificates or a program document describing the
terms and provisions of an Award or series of Awards under the Plan. The Committee may provide for the use of electronic, internet or
other non-paper Award Certificates, and the use of electronic, internet or other non-paper means for the acceptance thereof and actions
thereunder by a Participant.
(d) “Beneficial
Owner” shall have the meaning given such term in Rule 13d-3 of the General Rules and Regulations under the 1934 Act.
(e) “Board” means the Board of Directors of the Company.
(f) “Cause”
as a reason for a Participant’s termination of employment shall have the meaning assigned such term in the employment, consulting,
severance or similar agreement, if any, between such Participant and the Company or an Affiliate; provided, however, that
if there is no such employment, consulting, severance or similar agreement in which such term is defined, and unless otherwise defined
in the applicable Award Certificate, “Cause” shall mean any of the following acts by the Participant, as determined by the
Committee: (i) the commission of any act by the Participant constituting financial dishonesty against the Company or any of its Affiliates
(which act would be chargeable as a crime under applicable law); (ii) the Participant’s engaging in any other act of dishonesty,
fraud, intentional misrepresentation, moral turpitude, illegality or harassment which would: (A) materially adversely affect the
business or the reputation of the Company or any of its Affiliates with their respective then-current or prospective customers, suppliers,
lenders and/or other third parties with whom such entity does or might do business; or (B) expose the Company or any of its Affiliates
to a risk of civil or criminal legal damages, liabilities or penalties; (iii) the willful and repeated failure by the Participant
to follow the lawful directives of the Board or the Participant’s supervisor; (iv) any material misconduct, material violation
of the Company’s written policies, or willful and deliberate non-performance of duty by the Participant in connection with the business
affairs of the Company or any of its Affiliates; or (v) the Participant’s material breach of any employment, severance, non-competition,
non-solicitation, confidential information, or restrictive covenant agreement, or similar agreement, with the Company or an Affiliate.
The determination of the Committee as to the existence of “Cause” shall be conclusive on the Participant and the Company.
(g) “Change
in Control” means and includes the occurrence of any one of the following events but shall specifically exclude a Public Offering:
(i) during
any consecutive 12-month period, individuals who, at the beginning of such period, constitute the Board (the “Incumbent Directors”)
cease for any reason to constitute at least a majority of such Board, provided that any person becoming a director after the beginning
of such 12-month period and whose election or nomination for election was approved by a vote of at least a majority of the Incumbent Directors
then on the Board shall be an Incumbent Director; provided, however, that no individual initially elected or nominated as
a director of the Company as a result of an actual or threatened election contest with respect to the election or removal of directors
(“Election Contest”) or other actual or threatened solicitation of proxies or consents by or on behalf of any Person other
than the Board (“Proxy Contest”), including by reason of any agreement intended to avoid or settle any Election Contest or
Proxy Contest, shall be deemed an Incumbent Director; or
(ii) any
Person, other than a Principal Stockholder, becomes a Beneficial Owner, directly or indirectly, of either (A) 50% or more of the
then-outstanding shares of common stock of the Company (“Company Common Stock”) or (B) securities of the Company representing
50% or more of the combined voting power of the Company’s then outstanding securities eligible to vote for the election of directors
(the “Company Voting Securities”); provided, however, that for purposes of this subsection (ii), the following
acquisitions of Company Common Stock or Company Voting Securities shall not constitute a Change in Control: (w) an acquisition directly
or indirectly from the Company, (x) an acquisition by the Company or a Subsidiary, (y) an acquisition by any employee benefit
plan (or related trust) sponsored or maintained by the Company or any Subsidiary, or (z) an acquisition pursuant to a Non-Qualifying
Transaction (as defined in subsection (iii) below); or
(iii) the
consummation of a reorganization, merger, consolidation, statutory share exchange or similar form of corporate transaction involving
the Company or a Subsidiary (a “Reorganization”), or the sale or other disposition of all or substantially all of the
Company’s assets (a “Sale”) or the acquisition of assets or stock of another corporation or other entity (an
“Acquisition”), unless immediately following such Reorganization, Sale or Acquisition: (A) all or substantially all
of the individuals and entities who were the Beneficial Owners, respectively, of the outstanding Company Common Stock and
outstanding Company Voting Securities immediately prior to such Reorganization, Sale or Acquisition beneficially own, directly or
indirectly, more than 50% of, respectively, the then outstanding shares of common stock and the combined voting power of the then
outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the entity resulting
from such Reorganization, Sale or Acquisition (including, without limitation, an entity which as a result of such transaction owns
the Company or all or substantially all of the Company’s assets or stock either directly or through one or more subsidiaries,
the “Surviving Entity”) in substantially the same proportions as their ownership, immediately prior to such
Reorganization, Sale or Acquisition, of the outstanding Company Common Stock and the outstanding Company Voting Securities, as the
case may be, and (B) no person (other than (x) the Company or any Subsidiary, (y) the Surviving Entity or its
ultimate parent entity, or (z) any employee benefit plan (or related trust) sponsored or maintained by any of the foregoing) is
the Beneficial Owner, directly or indirectly, of 50% or more of the total common stock or 50% or more of the total voting power of
the outstanding voting securities eligible to elect directors of the Surviving Entity, and (C) at least a majority of the
members of the board of directors of the Surviving Entity were Incumbent Directors at the time of the Board’s approval of the
execution of the initial agreement providing for such Reorganization, Sale or Acquisition (any Reorganization, Sale or Acquisition
which satisfies all of the criteria specified in (A), (B) and (C) above shall be deemed to be a “Non-Qualifying
Transaction”).
(h) “Code”
means the Internal Revenue Code of 1986, as amended from time to time. For purposes of this Plan, references to sections of the Code
shall be deemed to include references to any applicable regulations thereunder and any successor or similar provision.
(i) “Committee”
means the committee of the Board described in Article 4.
(j) “Company”
means Checkpoint Therapeutics, Inc., a Delaware corporation, or any successor corporation.
(k) “Continuous
Service” means the absence of any interruption or termination of service as an employee, officer, consultant or director of the
Company or any Affiliate, as applicable; provided, however, that for purposes of an Incentive Stock Option “Continuous
Service” means the absence of any interruption or termination of service as an employee of the Company or any Parent or Subsidiary,
as applicable, pursuant to applicable tax regulations. Continuous Service shall not be considered interrupted in the following cases:
(i) a Participant transfers employment between the Company and an Affiliate or between Affiliates, (ii) in the discretion of
the Committee as specified at or prior to such occurrence, in the case of a spin-off, sale or disposition of the Participant’s
employer from the Company or any Affiliate, (iii) a Participant transfers from being an employee of the Company or an Affiliate
to being a director of the Company or of an Affiliate, or vice versa, (iv) in the discretion of the Committee as specified at or
prior to such occurrence, a Participant transfers from being an employee of the Company or an Affiliate to being a consultant to the
Company or of an Affiliate, or vice versa, or (v) any leave of absence authorized in writing by the Company prior to its commencement;
provided, however, that for purposes of Incentive Stock Options, no such leave may exceed 90 days, unless reemployment
upon expiration of such leave is guaranteed by statute or contract. If reemployment upon expiration of a leave of absence approved by
the Company is not so guaranteed, on the 91st day of such leave any Incentive Stock Option held by the Participant shall cease to be
treated as an Incentive Stock Option and shall be treated for tax purposes as a Nonstatutory Stock Option. Whether military, government
or other service or other leave of absence shall constitute a termination of Continuous Service shall be determined in each case by the
Committee at its discretion, and any determination by the Committee shall be final and conclusive; provided, however, that
for purposes of any Award that is subject to Code Section 409A, the determination of a leave of absence must comply with the requirements
of a “bona fide leave of absence” as provided in Treas. Reg. Section 1.409A-1(h).
(l) “Covered Employee”
means a covered employee as defined in Code Section 162(m)(3).
(m) “Deferred
Stock Unit” means a right granted to a Participant under Article 9 to receive Shares (or the equivalent value in cash or other
property if the Committee so provides) at a future time as determined by the Committee, or as determined by the Participant within guidelines
established by the Committee in the case of voluntary deferral elections.
(n) “Disability”
of a Participant means that the Participant is unable to engage in any substantial gainful activity by reason of any medically
determinable physical or mental impairment which can be expected to result in death or can be expected to last for a continuous
period of not less than 12 months. If the determination of Disability relates to an Incentive Stock Option, Disability means
Permanent and Total Disability as defined in Section 22(e)(3) of the Code. In the event of a dispute, the determination of
whether a Participant is Disabled will be made by the Committee and may be supported by the advice of a physician competent in the
area to which such Disability relates.
(o) “Dividend Equivalent” means a right granted with respect to an Award pursuant to Article 11.
(p) “Effective Date” has the meaning assigned such term in Section 3.1.
(q) “Eligible
Participant” means an employee, officer, consultant or director of the Company or any Affiliate.
(r) “Exchange”
means any national securities exchange on which the Stock may from time to time be listed or traded.
(s) “Fair
Market Value,” on any date, means (i) if the Stock is listed on an Exchange, the closing sales price on such Exchange on such
date or, in the absence of reported sales on such date, the closing sales price on the immediately preceding date on which sales were
reported, or (ii) if the Stock is not listed on an Exchange, the mean between the bid and offered prices as quoted by the applicable
interdealer quotation system for such date, provided that if the Stock is not quoted on an interdealer quotation system or it is determined
that the fair market value is not properly reflected by such quotations, Fair Market Value will be determined by such other method as
the Committee determines in good faith to be reasonable and in compliance with Code Section 409A.
(t) “Full-Value
Award” means an Award other than in the form of an Option or SAR, and which is settled by the issuance of Stock (or at the discretion
of the Committee, settled in cash valued by reference to Stock value).
(u) “Good
Reason” (or a similar term denoting constructive termination) has the meaning, if any, assigned such term in the employment, consulting,
severance or similar agreement, if any, between a Participant and the Company or an Affiliate; provided, however, that if
there is no such employment, consulting, severance or similar agreement in which such term is defined, “Good Reason” shall
have the meaning, if any, given such term in the applicable Award Certificate. If not defined in either such document, the term “Good
Reason” as used herein shall not apply to a particular Award.
(v) “Grant
Date” of an Award means the first date on which all necessary corporate action has been taken to approve the grant of the Award
as provided in the Plan, or such later date as is determined and specified as part of that authorization process. Notice of the grant
shall be provided to the grantee within a reasonable time after the Grant Date.
(w) “Incentive
Stock Option” means an Option that is intended to be an incentive stock option and meets the requirements of Section 422 of
the Code or any successor provision thereto.
(x) “Independent
Directors” means those members of the Board who qualify at any given time as an “independent” director under the applicable
rules of each Exchange on which the Shares are listed, as a “non-employee” director under Rule 16b-3 of the 1934
Act, and as an “outside” director under Section 162(m) of the Code.
(y) “Non-Employee
Director” means a director of the Company who is not a common law employee of the Company or an Affiliate.
(z) “Nonstatutory
Stock Option” means an Option that is not an Incentive Stock Option.
(aa)
“Option” means a right granted to a Participant under Article 7 of the Plan to purchase Stock at a specified price during
specified time periods. An Option may be either an Incentive Stock Option or a Nonstatutory Stock Option.
(bb)
“Other Stock-Based Award” means a right, granted to a Participant under Article 12, that relates to or is valued by reference
to Stock or other Awards relating to Stock.
(cc)
“Parent” means a corporation, limited liability company, partnership or other entity which owns or beneficially owns a majority
of the outstanding voting stock or voting power of the Company. Notwithstanding the above, with respect to an Incentive Stock Option,
Parent shall have the meaning set forth in Section 424(e) of the Code.
(dd)
“Participant” means an Eligible Participant who has been granted an Award under the Plan; provided that in the case of the
death of a Participant, the term “Participant” refers to a beneficiary designated pursuant to Section 14.4 or the legal
guardian or other legal representative acting in a fiduciary capacity on behalf of the Participant under applicable state law and court
supervision.
(ee) “Performance Award” means
any award granted under the Plan pursuant to Article 10.
(ff)
“Person” means any individual, entity or group, within the meaning of Section 3(a)(9) of the 1934 Act and as used
in Section 13(d)(3) or 14(d)(2) of the 1934 Act.
(gg)
“Plan” means the Checkpoint Therapeutics, Inc. Amended and Restated 2015 Incentive Plan, as amended from time to time.
(hh)
“Principal Stockholder” means Fortress Biotech, Inc., or any entity that is directly or indirectly affiliated with the
Principal Stockholder.
(ii) “Public
Offering” means a public offering of any class or series of the Company’s equity securities pursuant to a registration statement
filed by the Company under the 1933 Act or registration of the Company’s equity securities pursuant to Section 12(b) or
12(g) of the 1934 Act.
(jj)
“Qualified Performance-Based Award” means an Award that is either (i) intended to qualify for the Section 162(m) Exemption
and is made subject to performance goals based on Qualified Business Criteria as set forth in Section 11.2, or (ii) an Option
or SAR having an exercise price equal to or greater than the Fair Market Value of the underlying Stock as of the Grant Date.
(kk)
“Qualified Business Criteria” means one or more of the Business Criteria listed in Section 11.2 upon which performance
goals for certain Qualified Performance-Based Awards may be established by the Committee.
(ll)
“Restricted Stock” means Stock granted to a Participant under Article 9 that is subject to certain restrictions and to
risk of forfeiture.
(mm)
“Restricted Stock Unit” means the right granted to a Participant under Article 9 to receive shares of Stock (or the equivalent
value in cash or other property if the Committee so provides) in the future, which right is subject to certain restrictions and to risk
of forfeiture.
(nn)
“Section 162(m) Exemption” means the exemption from the limitation on deductibility imposed by Section 162(m) of
the Code that is set forth in Section 162(m)(4)(C) of the Code or any successor provision thereto.
(oo)
“Shares” means shares of the Company’s Stock. If there has been an adjustment or substitution with respect to the Shares
(whether or not pursuant to Article 14), the term “Shares” shall also include any shares of stock or other securities
that are substituted for Shares or into which Shares are adjusted.
(pp)
“Specified Employee” has the meaning given such term in Code Section 409A and the final regulations thereunder.
(qq)
“Stock” means the $0.001 par value common stock of the Company and such other securities of the Company as may be substituted
for Stock pursuant to Article 14.
(rr)
“Stock Appreciation Right” or “SAR” means a right granted to a Participant under Article 8 to receive a payment
equal to the difference between the Fair Market Value of a Share as of the date of exercise of the SAR over the base price of the SAR,
all as determined pursuant to Article 8.
(ss)
“Subsidiary” means any corporation, limited liability company, partnership or other entity of which a majority of the outstanding
voting stock or voting power is beneficially owned directly or indirectly by the Company. Notwithstanding
the above, with respect to an Incentive Stock Option, Subsidiary shall have the meaning set forth in Section 424(f) of the Code.
(tt) “1933 Act” means the Securities
Act of 1933, as amended from time to time.
(uu) “1934 Act” means the Securities
Exchange Act of 1934, as amended from time to time.
ARTICLE 3
EFFECTIVE TERM OF PLAN
3.1. EFFECTIVE
DATE. The Plan became effective on March 3, 2015 (the “Effective Date”). This second amended and restated of the
Plan will become effective on the date it is approved by the Company’s stockholders.
3.2. TERMINATION
OF PLAN. Unless earlier terminated as provided herein, the Plan shall continue in effect until the tenth anniversary of the date the
Company’s stockholders approve this second amended and restated of the Plan. The termination of the Plan on such date shall not
affect the validity of any Award outstanding on the date of termination, which shall continue to be governed by the applicable terms and
conditions of the Plan.
ARTICLE 4
ADMINISTRATION
4.1. COMMITTEE.
The Plan shall be administered by a Committee appointed by the Board (which Committee shall consist of at least two directors) or, at
the discretion of the Board from time to time, the Plan may be administered by the Board. It is intended that at least two of the directors
appointed to serve on the Committee shall be Independent Directors and that any members of the Committee who do not so qualify shall abstain
from participating in any decision to make or administer Awards that are made to Eligible Participants who at the time of consideration
for such Award (i) are persons subject to the short-swing profit rules of Section 16 of the 1934 Act or (ii) are reasonably
anticipated to become Covered Employees during the term of the Award. However, the mere fact that a Committee member shall fail to qualify
as an Independent Director or shall fail to abstain from such action shall not invalidate any Award made by the Committee which Award
is otherwise validly made under the Plan. The members of the Committee shall be appointed by, and may be changed at any time and from
time to time in the discretion of, the Board. Unless and until changed by the Board, the Compensation Committee of the Board is designated
as the Committee to administer the Plan. The Board may reserve to itself any or all of the authority and responsibility of the Committee
under the Plan or may act as administrator of the Plan for any and all purposes. To the extent the Board has reserved any authority and
responsibility or during any time that the Board is acting as administrator of the Plan, it shall have all the powers and protections
of the Committee hereunder, and any reference herein to the Committee (other than in this Section 4.1) shall include the Board. To
the extent any action of the Board under the Plan conflicts with actions taken by the Committee, the actions of the Board shall control.
4.2. ACTION
AND INTERPRETATIONS BY THE COMMITTEE. For purposes of administering the Plan, the Committee may from time to time adopt rules, regulations,
guidelines and procedures for carrying out the provisions and purposes of the Plan and make such other determinations, not inconsistent
with the Plan, as the Committee may deem appropriate. The Committee may correct any defect, supply any omission or reconcile any inconsistency
in the Plan or in any Award in the manner and to the extent it deems necessary to carry out the intent of the Plan. The Committee’s
interpretation of the Plan, any Awards granted under the Plan, any Award Certificate and all decisions and determinations by the Committee
with respect to the Plan are final, binding, and conclusive on all parties and shall be given the maximum deference permitted by applicable
law. Each member of the Committee is entitled to, in good faith, rely or act upon any report or other information furnished to that member
by any officer or other employee of the Company or any Affiliate, the Company’s or an Affiliate’s independent certified public
accountants, Company counsel or any executive compensation consultant or other professional retained by the Company or the Committee to
assist in the administration of the Plan. No member of the Committee will be liable for any good faith determination, act or omission
in connection with the Plan or any Award.
4.3. AUTHORITY
OF COMMITTEE. Except as provided in Section 4.1 hereof, the Committee has the exclusive power, authority and discretion to:
(a) grant Awards;
(b) designate Participants;
(c) determine the type or types of Awards to be granted to each Participant;
(d) determine the number of Awards to be granted and the number of Shares or dollar amount to which an Award will relate;
(e) determine the terms and conditions of any Award granted under the Plan;
(f) prescribe the form of each Award Certificate, which need not be identical for each Participant;
(g) decide all other matters that must be determined in connection with an Award;
(h) establish,
adopt or revise any rules, regulations, guidelines or procedures as it may deem necessary or advisable to administer the Plan;
(i) make
all other decisions and determinations that may be required under the Plan or as the Committee deems necessary or advisable to administer
the Plan;
(j) amend the Plan or any Award Certificate as provided herein; and
(k) adopt
such modifications, procedures, and subplans as may be necessary or desirable to comply with provisions of the laws of the United States
or any non-U.S. jurisdictions in which the Company or any Affiliate may operate, in order to assure the viability of the benefits of Awards
granted to participants located in the United States or such other jurisdictions and to further the objectives of the Plan.
Notwithstanding
any of the foregoing, grants of Awards to Non-Employee Directors hereunder shall
(i) be subject to the applicable award limits set forth in
Section 5.1 hereof, and (ii) be made only in accordance with the terms, conditions and parameters of a plan, program or
policy for the compensation of Non- Employee Directors as in effect from time to time that is approved and administered by the
Board. The Committee may not make other discretionary grants hereunder to Non-Employee Directors.
4.4. DELEGATION.
The Committee may, by resolution, expressly delegate to a special committee, consisting of one or more directors who may but need not
be officers of the Company, the authority, within specified parameters as to the number and terms of Awards, to (i) designate officers
and/or employees of the Company or any of its Affiliates to be recipients of Awards under the Plan, and (ii) to determine the number
of such Awards to be received by any such Participants; provided, however, that such delegation of duties and responsibilities
to an officer of the Company may not be made with respect to the grant of Awards to eligible participants (a) who are subject to
Section 16(a) of the 1934 Act at the Grant Date, or (b) who as of the Grant Date are reasonably anticipated to be become
Covered Employees during the term of the Award. The acts of such delegates shall be treated hereunder as acts of the Committee and such
delegates shall report regularly to the Committee regarding the delegated duties and responsibilities and any Awards so granted.
4.5. INDEMNIFICATION.
Each person who is or shall have been a member of the Committee, or of the Board, or an officer of the Company to whom authority was
delegated in accordance with this Article 4 shall be indemnified and held harmless by the Company against and from any loss,
cost, liability, or expense that may be imposed upon or reasonably incurred by him or her in connection with or resulting from any
claim, action, suit, or proceeding to which he or she may be a party or in which he or she may be involved by reason of any action
taken or failure to act under the Plan and against and from any and all amounts paid by him or her in settlement thereof, with the
Company’s approval, or paid by him or her in satisfaction of any judgment in any such action, suit, or proceeding against him
or her, provided he or she shall give the Company an opportunity, at its own expense, to handle and defend the same before he or she
undertakes to handle and defend it on his or her own behalf, unless such loss, cost, liability, or expense is a result of his or her
own willful misconduct or except as expressly provided by statute. The foregoing right of indemnification shall not be exclusive of
any other rights of indemnification to which such persons may be entitled under the Company’s charter or bylaws, as amended
from time to time, as a matter of law, or otherwise, or any power that the Company may have to indemnify them or hold them
harmless.
ARTICLE 5
SHARES SUBJECT TO THE PLAN
5.1. NUMBER
OF SHARES. Subject to adjustment as provided in Sections 5.2 and Section 15.1, the aggregate number of Shares reserved and available
for issuance pursuant to Awards granted under the Plan shall be 18,000,000. The maximum number of Shares that may be issued upon exercise
of Incentive Stock Options granted under the Plan shall be 12,000,000. The maximum aggregate number of Shares associated with any Award
granted under the Plan in any calendar year to any one Non-Employee Director shall be 100,000 Shares.
5.2. SHARE
COUNTING. Shares covered by an Award shall be subtracted from the Plan share reserve as of the Grant Date, but shall be added back
to the Plan share reserve in accordance with this Section 5.2.
(a) To
the extent that an Award is canceled, terminates, expires, is forfeited or lapses for any reason, any unissued or forfeited Shares originally
subject to the Award will be added back to the Plan share reserve and again be available for issuance pursuant to Awards granted under
the Plan.
(b) Shares
subject to Awards settled in cash will be added back to the Plan share reserve and again be available for issuance pursuant to Awards
granted under the Plan.
(c) Shares
withheld or repurchased from an Award or delivered by a Participant to satisfy minimum tax withholding requirements will be added back
to the Plan share reserve and again be available for issuance pursuant to Awards granted under the Plan.
(d) If
the exercise price of an Option is satisfied in whole or in part by delivering Shares to the Company (by either actual delivery or attestation),
the number of Shares so tendered (by delivery or attestation) shall be added to the Plan share reserve and will be available for issuance
pursuant to Awards granted under the Plan.
(e) To
the extent that the full number of Shares subject to an Option or SAR is not issued upon exercise of the Option or SAR for any reason,
including by reason of net-settlement of the Award, the unissued Shares originally subject to the Award will be added back to the Plan
share reserve and again be available for issuance pursuant to other Awards granted under the Plan.
(f) To
the extent that the full number of Shares subject to an Award other than an Option or SAR is not issued for any reason, including by reason
of failure to achieve maximum performance goals, the unissued Shares originally subject to the Award will be added back to the Plan share
reserve and again be available for issuance pursuant to Awards granted under the Plan.
(g) Substitute
Awards granted pursuant to Section 14.9 of the Plan shall not count against the Shares otherwise available for issuance under the
Plan under Section 5.1.
(h) Subject
to applicable Exchange requirements, shares available under a stockholder-approved plan of a company acquired by the Company (as appropriately
adjusted to Shares to reflect the transaction) may be issued under the Plan pursuant to Awards granted to individuals who were not employees
of the Company or its Affiliates immediately before such transaction and will not count against the maximum share limitation specified
in Section 5.1.
5.3. STOCK
DISTRIBUTED. Any Stock distributed pursuant to an Award may consist, in whole or in part, of authorized and unissued Stock, treasury
Stock or Stock purchased on the open market.
5.4. LIMITATION
ON AWARDS. Notwithstanding any provision in the Plan to the contrary (but subject to adjustment as provided in Article 15):
(a) Options.
The maximum number of Options granted under the Plan in any calendar year to any one Participant shall be for 12,000,000 Shares.
(b) SARs.
The maximum number of Stock Appreciation Rights granted under the Plan in any calendar year to any one Participant shall be with respect
to 12,000,000 Shares.
(c) Performance
Awards. With respect to any calendar year (i) the maximum amount that may be paid to any one Participant for Performance Awards payable
in cash or property other than Shares shall be $10,000,000, and (ii) the maximum number of Shares that may be paid to any one Participant
for Performance Awards payable in Stock shall be 12,000,000 Shares. For purposes of applying these limits in the case of multi-year performance
periods, the amount of cash or property or number of Shares deemed paid with respect to any calendar year is the total amount payable
or Shares earned for the performance period divided by the number of calendar years in the performance period.
ARTICLE 6
ELIGIBILITY
6.1. GENERAL.
Awards may be granted only to Eligible Participants. Incentive Stock Options may be granted only to Eligible Participants who are employees
of the Company or a Parent or Subsidiary as defined in Section 424(e) and (f) of the Code. Eligible Participants who are
service providers to an Affiliate may be granted Options or SARs under this Plan only if the Affiliate qualifies as an “eligible
issuer of service recipient stock” within the meaning of Treas. Reg. Section 1.409A-1(b)(5)(iii)(E) of the final regulations
under Code Section 409A.
ARTICLE 7
STOCK OPTIONS
7.1. GENERAL.
The Committee is authorized to grant Options to Participants on the following terms and conditions:
(a) EXERCISE
PRICE. The exercise price per Share under an Option shall be determined by the Committee, provided that the exercise price for any
Option (other than an Option issued as a substitute Award pursuant to Section 14.9) shall not be less than the Fair Market Value
as of the Grant Date.
(b) PROHIBITION
ON REPRICING. Except as otherwise provided in Article 14, without the prior approval of stockholders of the Company: (i) the
exercise price of an Option may not be reduced, directly or indirectly, (ii) an Option may not be cancelled in exchange for cash,
other Awards, or Options or SARs with an exercise or base price that is less than the exercise price of the original Option, or otherwise,
and (iii) the Company may not repurchase an Option for value (in cash or otherwise) from a Participant if the current Fair Market
Value of the Shares underlying the Option is lower than the exercise price per share of the Option
(c) TIME
AND CONDITIONS OF EXERCISE. The Committee shall determine the time or times at which an Option may be exercised in whole or in part,
subject to Section 7.1(e). The Committee shall also determine the performance or other conditions, if any, that must be satisfied
before all or part of an Option may be exercised or vested.
(d) PAYMENT.
The Committee shall determine the methods by which the exercise price of an Option may be paid, the form of payment, and the methods by
which Shares shall be delivered or deemed to be delivered to Participants. As determined by the Committee at or after the Grant Date,
payment of the exercise price of an Option may be made, in whole or in part, in the form of (i) cash or cash equivalents, (ii) delivery
(by either actual delivery or attestation) of previously-acquired Shares based on the Fair Market Value of the Shares on the date the
Option is exercised, (iii) withholding of Shares from the Option based on the Fair Market Value of the Shares on the date the Option
is exercised, (iv) broker- assisted market sales, or (iv) any other “cashless exercise” arrangement.
(e) EXERCISE
TERM. Except for Nonstatutory Options granted to Participants outside the United States, no Option granted under the Plan shall be
exercisable for more than ten years from the Grant Date.
(f) NO
DEFERRAL FEATURE. No Option shall provide for any feature for the deferral of compensation other than the deferral of recognition
of income until the exercise or disposition of the Option.
(g) NO DIVIDEND EQUIVALENTS. No Option shall provide for Dividend Equivalents.
7.2. INCENTIVE
STOCK OPTIONS. The terms of any Incentive Stock Options granted under the Plan must comply with the requirements of Section 422
of the Code. Without limiting the foregoing, any Incentive Stock Option granted to a Participant who at the Grant Date owns more than
10% of the voting power of all classes of shares of the Company must have an exercise price per Share of not less than 110% of the Fair
Market Value per Share on the Grant Date and an Option term of not more than five years. If all of the requirements of Section 422
of the Code (including the above) are not met, the Option shall automatically become a Nonstatutory Stock Option.
ARTICLE 8
STOCK APPRECIATION RIGHTS
8.1. GRANT
OF STOCK APPRECIATION RIGHTS. The Committee is authorized to grant Stock Appreciation Rights to Participants on the following terms
and conditions:
(a) RIGHT
TO PAYMENT. Upon the exercise of a SAR, the Participant has the right to receive, for each Share with respect to which the SAR is
being exercised, the excess, if any, of (i) the Fair Market Value of one Share on the date of exercise; over (ii) the base price
of the SAR as determined by the Committee and set forth in the Award Certificate, which shall not be less than the Fair Market Value of
one Share on the Grant Date.
(b) PROHIBITION
ON REPRICING. Except as otherwise provided in Article 14, without the prior approval of stockholders of the Company:
(i) the base price of a SAR may not be reduced, directly or indirectly, (ii) a SAR may not be cancelled in exchange for
cash, other Awards, or Options or SARs with an exercise or base price that is less than the base price of the original SAR, or
otherwise, and (iii) the Company may not repurchase a SAR for value (in cash or otherwise) from a Participant if the current
Fair Market Value of the Shares underlying the SAR is lower than the base price per share of the SAR.
(c) TIME
AND CONDITIONS OF EXERCISE. The Committee shall determine the time or times at which a SAR may be exercised in whole or in part. Except
for SARs granted to Participants outside the United States, no SAR shall be exercisable for more than ten years from the Grant Date.
(d) NO
DEFERRAL FEATURE. No SAR shall provide for any feature for the deferral of compensation other than the deferral of recognition of
income until the exercise or disposition of the SAR.
(e) NO DIVIDEND EQUIVALENTS. No SAR shall provide for Dividend Equivalents.
(f) OTHER
TERMS. All SARs shall be evidenced by an Award Certificate. Subject to the limitations of this Article 8, the terms, methods
of exercise, methods of settlement, form of consideration payable in settlement (e.g., cash, Shares or other property), and any other
terms and conditions of the SAR shall be determined by the Committee at the time of the grant and shall be reflected in the Award Certificate.
ARTICLE 9
RESTRICTED STOCK, RESTRICTED
STOCK UNITS AND DEFERRED STOCK UNITS
9.1. GRANT
OF RESTRICTED STOCK, RESTRICTED STOCK UNITS AND DEFERRED STOCK UNITS. The Committee is authorized to make Awards of Restricted Stock,
Restricted Stock Units or Deferred Stock Units to Participants in such amounts and subject to such terms and conditions as may be selected
by the Committee. An Award of Restricted Stock, Restricted Stock Units or Deferred Stock Units shall be evidenced by an Award Certificate
setting forth the terms, conditions, and restrictions applicable to the Award.
9.2. ISSUANCE
AND RESTRICTIONS. Restricted Stock, Restricted Stock Units or Deferred Stock Units shall be subject to such restrictions on
transferability and other restrictions as the Committee may impose (including, for example, limitations on the right to vote
Restricted Stock or the right to receive dividends on the Restricted Stock). These restrictions may lapse separately or in
combination at such times, under such circumstances, in such installments, upon the satisfaction of performance goals or otherwise,
as the Committee determines at the time of the grant of the Award or thereafter. Except as otherwise provided in an Award
Certificate or any special Plan document governing an Award, a Participant shall have all of the rights of a stockholder with
respect to Restricted Stock, but none of the rights of a stockholder with respect to Restricted Stock Units or Deferred Stock Units
until such time as Shares of Stock are paid in settlement of such Awards. Unless otherwise provided in the applicable Award
Certificate, Restricted Stock will be entitled to full dividend rights, and any dividends paid thereon will be paid or distributed
to the holder no later than the end of the calendar year in which the dividends are paid to stockholders or, if later, the 15th day
of the third month following the date the dividends are paid to stockholders.
9.3. FORFEITURE.
Subject to the terms of the Award Certificate and except as otherwise determined by the Committee at the time of the grant of the Award
or thereafter, upon termination of Continuous Service during the applicable restriction period or upon failure to satisfy a performance
goal during the applicable restriction period, Restricted Stock or Restricted Stock Units that are at that time subject to restrictions
shall be forfeited.
9.4. DELIVERY
OF RESTRICTED STOCK. Shares of Restricted Stock shall be delivered to the Participant at the Grant Date either by book-entry registration
or by delivering to the Participant, or a custodian or escrow agent (including, without limitation, the Company or one or more of its
employees) designated by the Committee, a stock certificate or certificates registered in the name of the Participant. If physical certificates
representing shares of Restricted Stock are registered in the name of the Participant, such certificates must bear an appropriate legend
referring to the terms, conditions, and restrictions applicable to such Restricted Stock.
ARTICLE 10
PERFORMANCE AWARDS
10.1. GRANT
OF PERFORMANCE AWARDS. The Committee is authorized to grant any Award under this Plan, including cash-based Awards, with performance-based
vesting criteria, on such terms and conditions as may be selected by the Committee. Any such Awards with performance-based vesting criteria
are referred to herein as Performance Awards. The Committee shall have the complete discretion to determine the number of Performance
Awards granted to each Participant, subject to Section 5.4, and to designate the provisions of such Performance Awards as provided
in Section 4.3. All Performance Awards shall be evidenced by an Award Certificate or a written program established by the Committee,
pursuant to which Performance Awards are awarded under the Plan under uniform terms, conditions and restrictions set forth in such written
program.
10.2. PERFORMANCE
GOALS. The Committee may establish performance goals for Performance Awards which may be based on any criteria selected by the Committee.
Such performance goals may be described in terms of Company-wide objectives or in terms of objectives that relate to the performance of
the Participant, an Affiliate or a division, region, department or function within the Company or an Affiliate. If the Committee determines
that a change in the business, operations, corporate structure or capital structure of the Company or the manner in which the Company
or an Affiliate conducts its business, or other events or circumstances render performance goals to be unsuitable, the Committee may modify
such performance goals in whole or in part, as the Committee deems appropriate. If a Participant is promoted, demoted or transferred to
a different business unit or function during a performance period, the Committee may determine that the performance goals or performance
period are no longer appropriate and may (i) adjust, change or eliminate the performance goals or the applicable performance period
as it deems appropriate to make such goals and period comparable to the initial goals and period, or (ii) make a cash payment to
the participant in an amount determined by the Committee. The foregoing two sentences shall not apply with respect to a Performance Award
that is intended to be a Qualified Performance-Based Award if the recipient of such award (a) was a Covered Employee on the date
of the modification, adjustment, change or elimination of the performance goals or performance period, or (b) in the reasonable judgment
of the Committee, may be a Covered Employee on the date the Performance Award is expected to be paid.
ARTICLE 11
QUALIFIED PERFORMANCE-BASED
AWARDS
11.1. OPTIONS
AND STOCK APPRECIATION RIGHTS. The provisions of the Plan are intended to enable Options and Stock Appreciation Rights granted hereunder
to any Covered Employee to qualify for the Section 162(m) Exemption.
11.2. OTHER
AWARDS. When granting any other Award, the Committee may designate such Award as a Qualified Performance-Based Award, based upon a
determination that the recipient is or may be a Covered Employee with respect to such Award, and the Committee wishes such Award to qualify
for the Section 162(m) Exemption. If an Award is so designated, the Committee shall establish performance goals for such Award
within the time period prescribed by Section 162(m) of the Code based on one or more of the following Qualified Business Criteria,
which may be expressed in terms of Company-wide objectives or in terms of objectives that relate to the performance of an Affiliate or
a division, region, department or function within the Company or an Affiliate:
| — | Profit (net profit, gross profit, operating profit, economic profit, profit margins or other corporate profit measures) |
| — | Earnings (EBIT, EBITDA, earnings per share, or other corporate earnings measures) |
| — | Net income (before or after taxes, operating income or other income measures) |
| — | Cash (cash flow, cash generation or other cash measures) |
| — | Stock price or performance |
| — | Total shareholder return (stock price appreciation plus reinvested dividends divided by beginning share price) |
| — | Return measures (including, but not limited to, return on assets, capital, equity, investments or sales, and cash flow return on assets,
capital, equity, or sales); |
| — | Improvements in capital structure |
| — | Expenses (expense management, expense ratio, expense efficiency ratios or other expense measures) |
| — | Business expansion or consolidation (acquisitions, divestitures, in-licensing or product acquisitions) |
| — | Clinical and regulatory milestones |
| — | Corporate financing activities |
| — | Supply, production and manufacturing milestones |
| — | Corporate partnerships or strategic alliances |
Performance
goals with respect to the foregoing Qualified Business Criteria may be specified in absolute terms, on an adjusted basis, in
percentages, or in terms of growth from period to period or growth rates over time, as well as measured relative to the performance
of a group of comparator companies, or a published or special index, or a stock market index, that the Committee deems appropriate.
Any member of a comparator group or an index that ceases to exist during a measurement period shall be disregarded for the entire
measurement period. Performance Goals need not be based upon an increase or positive result under a business criterion and could
include, for example, the maintenance of the status quo or the limitation of economic losses (measured, in each case, by reference
to a specific business criterion). Performance measures may but need not be determinable in conformance with generally accepted
accounting principles.
11.3. PERFORMANCE
GOALS. Each Qualified Performance-Based Award (other than a market- priced Option or SAR) shall be earned, vested and payable
(as applicable) only upon the achievement of performance goals established by the Committee based upon one or more of the Qualified
Business Criteria, together with the satisfaction of any other conditions, such as continued employment, as the Committee may
determine to be appropriate; provided, however, that the Committee may provide, either in connection with the grant
thereof or by amendment thereafter, that achievement of such performance goals will be waived, in whole or in part, upon
(i) the termination of employment of a Participant by reason of death or Disability, or
(ii) the occurrence of a Change in Control. In addition, the Committee has the right, in
connection with the grant of a Qualified Performance-Based Award, to exercise negative discretion to determine that the portion of
such Award actually earned, vested and/or payable (as applicable) shall be less than the portion that would be earned, vested and/or
payable based solely upon application of the applicable performance goals.
11.4. INCLUSIONS
AND EXCLUSIONS FROM PERFORMANCE CRITERIA. The Committee may provide in any Qualified Performance-Based Award, at the time the
performance goals are established, that any evaluation of performance shall exclude or otherwise objectively adjust for any
specified circumstance or event that occurs during a performance period, including by way of example but without limitation the
following: (a) asset write-downs or impairment charges; (b) litigation or claim judgments or settlements; (c) the
effect of changes in tax laws, accounting principles or other laws or provisions affecting reported results;
(d) accruals for reorganization and restructuring programs; (e) unusual or
infrequently occurring items as described in management’s discussion and analysis of financial condition and results of
operations appearing in the Company’s annual report to stockholders for the applicable year; (f) acquisitions or
divestitures; (g) any other specific, unusual or nonrecurring events, or objectively determinable category thereof, including
discontinued operations or a change in our fiscal year, and (h) foreign exchange gains and losses. To the extent such
inclusions or exclusions affect Awards to Covered Employees, they shall be prescribed in a form that meets the requirements of Code
Section 162(m) for deductibility.
11.5. CERTIFICATION
OF PERFORMANCE GOALS. Any payment of a Qualified Performance- Based Award granted with performance goals pursuant to Section 11.3
above shall be conditioned on the written certification of the Committee in each case that the performance goals and any other material
conditions were satisfied. Except as specifically provided in Section 11.3, no Qualified Performance-Based Award held by a Covered
Employee or by an employee who in the reasonable judgment of the Committee may be a Covered Employee on the date of payment, may be amended,
nor may the Committee exercise any discretionary authority it may otherwise have under the Plan with respect to a Qualified Performance-Based
Award under the Plan, in any manner to waive the achievement of the applicable performance goal based on Qualified Business Criteria or
to increase the amount payable pursuant thereto or the value thereof, or otherwise in a manner that would cause the Qualified Performance-Based
Award to cease to qualify for the Section 162(m) Exemption.
11.6. AWARD
LIMITS. Section 5.4 sets forth (i) the maximum number of Shares that may be granted in any one-year period to a Participant
in designated forms of stock-based Awards, and (ii) the maximum aggregate dollar amount that may be paid with respect to cash-based
Awards under the Plan to any one Participant in any fiscal year of the Company.
ARTICLE 12
DIVIDEND EQUIVALENTS
12.1. GRANT
OF DIVIDEND EQUIVALENTS. The Committee is authorized to grant Dividend Equivalents with respect to Full-Value Awards granted
hereunder, subject to such terms and conditions as may be selected by the Committee. Dividend Equivalents shall entitle the
Participant to receive payments equal to ordinary cash dividends or distributions with respect to all or a portion of the number of
Shares subject to a Full-Value Award, as determined by the Committee. The Committee may provide that Dividend Equivalents will be
paid or distributed when accrued or be deemed to have been reinvested in additional Shares or otherwise reinvested. Unless otherwise
provided by the Committee or in the Award Certificate, Dividend Equivalents will be paid or distributed to the Participant no later
than the end of the calendar year in which the dividends are paid to stockholders or, if later, the 15th day of the third month
following the date the dividends are paid to stockholders.
ARTICLE 13
STOCK OR OTHER STOCK-BASED AWARDS
13.1. GRANT
OF STOCK OR OTHER STOCK-BASED AWARDS. The Committee is authorized, subject to limitations under applicable law, to grant to Participants
such other Awards that are payable in, valued in whole or in part by reference to, or otherwise based on or related to Shares, as deemed
by the Committee to be consistent with the purposes of the Plan, including without limitation Shares awarded purely as a “bonus”
and not subject to any restrictions or conditions, convertible or exchangeable debt securities, other rights convertible or exchangeable
into Shares, and Awards valued by reference to book value per Share or the value of securities of or the performance of specified Parents
or Subsidiaries. The Committee shall determine the terms and conditions of such Awards.
ARTICLE 14
PROVISIONS APPLICABLE TO AWARDS
14.1. AWARD
CERTIFICATES. Each Award shall be evidenced by an Award Certificate. Each Award Certificate shall include such provisions, not inconsistent
with the Plan, as may be specified by the Committee.
14.2. FORM OF
PAYMENT FOR AWARDS. At the discretion of the Committee, payment of Awards may be made in cash, Stock, a combination of cash and Stock,
or any other form of property as the Committee shall determine. In addition, payment of Awards may include such terms, conditions, restrictions
and/or limitations, if any, as the Committee deems appropriate, including, in the case of Awards paid in the form of Stock, restrictions
on transfer and forfeiture provisions. Further, payment of Awards may be made in the form of a lump sum, or in installments, as determined
by the Committee.
14.3. LIMITS
ON TRANSFER. No right or interest of a Participant in any unexercised or restricted Award may be pledged, encumbered, or
hypothecated to or in favor of any party other than the Company or an Affiliate, or shall be subject to any lien, obligation, or
liability of such Participant to any other party other than the Company or an Affiliate. No unexercised or restricted Award shall be
assignable or transferable by a Participant other than by will or the laws of descent and distribution; provided, however,
that Nonstatutory Stock Options may be transferred without consideration to members of a Participant’s immediate family
(“Immediate Family Members”), to trusts in which such Immediate Family Members have more than fifty percent (50%) of the
beneficial interest, to foundations in which such Immediate Family Members (or the Participant) control the management of assets,
and to any other entity (including limited partnerships and limited liability companies) in which the Immediate Family Members (or
the Participant) own more than fifty percent (50%) of the voting interest; and, provided, further, that the Committee
may (but need not) permit other transfers (other than transfers for value) where the Committee concludes that such transferability
(i) does not result in accelerated taxation, (ii) does not cause any Option intended to be an Incentive Stock Option to
fail to be described in Code Section 422(b), and (iii) is otherwise appropriate and desirable, taking into account any
factors deemed relevant, including without limitation, state or federal tax or securities laws applicable to transferable
Awards.
14.4. BENEFICIARIES.
Notwithstanding Section 14.3, a Participant may, in the manner determined by the Committee, designate a beneficiary to exercise the
rights of the Participant and to receive any distribution with respect to any Award upon the Participant’s death. A beneficiary,
legal guardian, legal representative, or other person claiming any rights under the Plan is subject to all terms and conditions of the
Plan and any Award Certificate applicable to the Participant, except to the extent the Plan and Award Certificate otherwise provide, and
to any additional restrictions deemed necessary or appropriate by the Committee. If no beneficiary has been designated or survives the
Participant, any payment due to the Participant shall be made to the Participant’s estate. Subject to the foregoing, a beneficiary
designation may be changed or revoked by a Participant, in the manner provided by the Company, at any time provided the change or revocation
is filed with the Committee.
14.5. STOCK
TRADING RESTRICTIONS. All Stock issuable under the Plan is subject to any stop- transfer orders and other restrictions as the Committee
deems necessary or advisable to comply with federal or state securities laws, rules and regulations and the rules of any Exchange
or automated quotation system on which the Stock is listed, quoted, or traded. The Committee may place legends on any Stock certificate
or issue instructions to the transfer agent to reference restrictions applicable to the Stock.
14.6. EFFECT
OF A CHANGE IN CONTROL. Upon the occurrence of a Change in Control: (i) outstanding Options, SARs, and other Awards in the
nature of rights that may be exercised shall become fully exercisable, (ii) time-based vesting restrictions on outstanding
Awards shall lapse, and (iii) the target payout opportunities attainable under outstanding performance-based Awards shall be
deemed to have been fully earned as of the effective date of the Change in Control based upon an assumed achievement of all relevant
performance goals at the “target” level, and there shall be a prorata payout to Participants within sixty (60) days
following the Change in Control (unless a later date is required by Section 17.3 hereof), based upon the length of time within
the performance period that has elapsed prior to the Change in Control. Any Awards shall thereafter continue or lapse in accordance
with the other provisions of the Plan and the Award Certificate. To the extent that this provision causes Incentive Stock Options to
exceed the dollar limitation set forth in Code Section 422(d), the excess Options shall be deemed to be Nonstatutory Stock
Options.
14.7. ACCELERATION
FOR ANY OTHER REASON. Regardless of whether an event has occurred as described in Section 14.6 above, the Committee may in its
sole discretion at any time determine that all or a portion of a Participant’s Options, SARs, and other Awards in the nature of
rights that may be exercised shall become fully or partially exercisable, that all or a part of the time-based vesting restrictions on
all or a portion of the outstanding Awards shall lapse, and/or that any performance-based criteria with respect to any Awards shall be
deemed to be wholly or partially satisfied, in each case, as of such date as the Committee may, in its sole discretion, declare. The Committee
may discriminate among Participants and among Awards granted to a Participant in exercising its discretion pursuant to this Section 14.7.
Notwithstanding anything in the Plan, including this Section 14.7, the Committee may not accelerate the payment of any Award if such
acceleration would violate Section 409A(a)(3) of the Code.
14.8. FORFEITURE
EVENTS. Awards under the Plan shall be subject to any compensation recoupment policy that the Company may adopt from time to time
that is applicable by its terms to the Participant. In addition, the Committee may specify in an Award Certificate that the Participant’s
rights, payments and benefits with respect to an Award shall be subject to reduction, cancellation, forfeiture or recoupment upon the
occurrence of certain specified events, in addition to any otherwise applicable vesting or performance conditions of an Award. Such events
may include, but shall not be limited to, (i) termination of employment for cause, (ii) violation of material Company or Affiliate
policies, (iii) breach of noncompetition, confidentiality or other restrictive covenants that may apply to the Participant, (iv) other
conduct by the Participant that is detrimental to the business or reputation of the Company or any Affiliate, or (v) a later determination
that the vesting of, or amount realized from, a Performance Award was based on materially inaccurate financial statements or any other
materially inaccurate performance metric criteria, whether or not the Participant caused or contributed to such material inaccuracy.
14.9. SUBSTITUTE
AWARDS. The Committee may grant Awards under the Plan in substitution for stock and stock-based awards held by employees of another
entity who become employees of the Company or an Affiliate as a result of a merger or consolidation of the former employing entity with
the Company or an Affiliate or the acquisition by the Company or an Affiliate of property or stock of the former employing corporation.
The Committee may direct that the substitute awards be granted on such terms and conditions as the Committee considers appropriate in
the circumstances.
ARTICLE 15
CHANGES IN CAPITAL STRUCTURE
15.1. MANDATORY
ADJUSTMENTS. In the event of a nonreciprocal transaction between the Company and its stockholders that causes the per-share
value of the Stock to change (including, without limitation, any stock dividend, stock split, spin-off, rights offering, or large
nonrecurring cash dividend), the Committee shall make such adjustments to the Plan and Awards as it deems necessary, in its sole
discretion, to prevent dilution or enlargement of rights immediately resulting from such transaction. Action by the Committee may
include: (i) adjustment of the number and kind of shares that may be delivered under the Plan; (ii) adjustment of the
number and kind of shares subject to outstanding Awards; (iii) adjustment of the exercise price of outstanding Awards or the
measure to be used to determine the amount of the benefit payable on an Award; and (iv) any other adjustments that the
Committee determines to be equitable. Notwithstanding the foregoing, the Committee shall not make any adjustments to outstanding
Options or SARs that would constitute a modification or substitution of the stock right under Treas. Reg.
Section 1.409A-1(b)(5)(v) that would be treated as the grant of a new stock right or change in the form of payment for
purposes of Code Section 409A. Without limiting the foregoing, in the event of a subdivision of the outstanding Stock (stock-
split), a declaration of a dividend payable in Shares, or a combination or consolidation of the outstanding Stock into a lesser
number of Shares, the authorization limits under Sections 5.1 and 5.4 shall automatically be adjusted proportionately, and the
Shares then subject to each Award shall automatically, without the necessity for any additional action by the Committee, be adjusted
proportionately without any change in the aggregate purchase price therefor.
15.2 DISCRETIONARY
ADJUSTMENTS. Upon the occurrence or in anticipation of any corporate event or transaction involving the Company (including, without
limitation, any merger, reorganization, recapitalization, combination or exchange of shares, or any transaction described in Section 15.1),
the Committee may, in its sole discretion, provide (i) that Awards will be settled in cash rather than Stock, (ii) that Awards
will become immediately vested and non-forfeitable and exercisable (in whole or in part) and will expire after a designated period of
time to the extent not then exercised, (iii) that Awards will be assumed by another party to a transaction or otherwise be equitably
converted or substituted in connection with such transaction, (iv) that outstanding Awards may be settled by payment in cash or cash
equivalents equal to the excess of the fair market value of the underlying Stock, as of a specified date associated with the transaction
(or the per-shares transaction price), over the exercise or base price of the Award, (v) that performance targets and performance
periods for Performance Awards will be modified, consistent with Code Section 162(m) where applicable, or (vi) any combination
of the foregoing. The Committee’s determination need not be uniform and may be different for different Participants whether or not
such Participants are similarly situated.
15.3 GENERAL.
Any discretionary adjustments made pursuant to this Article 14 shall be subject to the provisions of Section 16.2. To the extent
that any adjustments made pursuant to this Article 14 cause Incentive Stock Options to cease to qualify as Incentive Stock Options,
such Options shall be deemed to be Nonstatutory Stock Options.
ARTICLE 16
AMENDMENT, MODIFICATION AND
TERMINATION
16.1. AMENDMENT,
MODIFICATION AND TERMINATION. The Board or the Committee may, at any time and from time to time, amend, modify or terminate the
Plan without stockholder approval; provided, however, that if an amendment to the Plan would, in the reasonable
opinion of the Board or the Committee, constitute a material change requiring stockholder approval under applicable laws, policies
or regulations or the applicable listing or other requirements of an Exchange, then such amendment shall be subject to stockholder
approval; and provided, further, that the Board or Committee may condition any other amendment or modification on the
approval of stockholders of the Company for any reason, including by reason of such approval being necessary or deemed advisable
(i) to comply with the listing or other requirements of an Exchange, or (ii) to satisfy any other tax, securities or other
applicable laws, policies or regulations. Except for any mandatory adjustments to the Plan and Awards contemplated by
Section 15.1, without the prior approval of the stockholders of the Company, the Plan may not be amended to permit:
(i) the exercise price or base price of an Option or SAR to be reduced, directly or indirectly, (ii) an Option or SAR to
be cancelled in exchange for cash, other Awards, or Options or SARs with an exercise or base price that is less than the exercise
price or base price of the original Option or SAR, or otherwise, or (iii) the Company to repurchase an Option or SAR for value
(in cash or otherwise) from a Participant if the current Fair Market Value of the Shares underlying the Option or SAR is lower than
the exercise price or base price per share of the Option or SAR.
16.2. AWARDS
PREVIOUSLY GRANTED. At any time and from time to time, the Committee may amend, modify or terminate any outstanding Award without
approval of the Participant; provided, however:
(a) Subject
to the terms of the applicable Award Certificate, such amendment, modification or termination shall not, without the
Participant’s consent, reduce or diminish the value of such Award determined as if the Award had been exercised, vested,
cashed in or otherwise settled on the date of such amendment or termination (with the per-share value of an Option or SAR for this
purpose being calculated as the excess, if any, of the Fair Market Value as of the date of such amendment or termination over the
exercise or base price of such Award);
(b) The
original term of an Option or SAR may not be extended without the prior approval of the stockholders of the Company;
(c) Except
as otherwise provided in Article 14, without the prior approval of the stockholders of the Company: (i) the exercise price or
base price of an Option or SAR may not be reduced, directly or indirectly, (ii) an Option or SAR may not be cancelled in exchange
for cash, other Awards, or Options or SARs with an exercise or base price that is less than the exercise price or base price of the original
Option or SAR, or otherwise, and (iii) the Company may not repurchase an Option or SAR for value (in cash or otherwise) from a Participant
if the current Fair Market Value of the Shares underlying the Option or SAR is lower than the exercise price or base price per share of
the Option or SAR; and
(d) No
termination, amendment, or modification of the Plan shall adversely affect any Award previously granted under the Plan, without the written
consent of the Participant affected thereby. An outstanding Award shall not be deemed to be “adversely affected” by a Plan
amendment if such amendment would not reduce or diminish the value of such Award determined as if the Award had been exercised, vested,
cashed in or otherwise settled on the date of such amendment (with the per-share value of an Option or SAR for this purpose being calculated
as the excess, if any, of the Fair Market Value as of the date of such amendment over the exercise or base price of such Award).
16.3. COMPLIANCE
AMENDMENTS. Notwithstanding anything in the Plan or in any Award Certificate to the contrary, the Board may amend the Plan or an Award
Certificate, to take effect retroactively or otherwise, as deemed necessary or advisable for the purpose of conforming the Plan or Award
Certificate to any present or future law relating to plans of this or similar nature (including, but not limited to, Section 409A
of the Code), and to the administrative regulations and rulings promulgated thereunder. By accepting an Award under this Plan, a Participant
agrees to any amendment made pursuant to this Section 16.3 to any Award granted under the Plan without further consideration or action.
ARTICLE 17
GENERAL PROVISIONS
17.1. RIGHTS OF PARTICIPANTS.
(a) No
Participant or any Eligible Participant shall have any claim to be granted any Award under the Plan. Neither the Company, its Affiliates
nor the Committee is obligated to treat Participants or Eligible Participants uniformly, and determinations made under the Plan may be
made by the Committee selectively among Eligible Participants who receive, or are eligible to receive, Awards (whether or not such Eligible
Participants are similarly situated).
(b) Nothing
in the Plan, any Award Certificate or any other document or statement made with respect to the Plan, shall interfere with or limit in
any way the right of the Company or any Affiliate to terminate any Participant’s employment or status as an officer, or any Participant’s
service as a director, at any time, nor confer upon any Participant any right to continue as an employee, officer, or director of the
Company or any Affiliate, whether for the duration of a Participant’s Award or otherwise.
(c) Neither
an Award nor any benefits arising under this Plan shall constitute an employment contract with the Company or any Affiliate and, accordingly,
subject to Article 15, this Plan and the benefits hereunder may be terminated at any time in the sole and exclusive discretion of
the Committee without giving rise to any liability on the part of the Company or any of its Affiliates.
(d) No
Award gives a Participant any of the rights of a stockholder of the Company unless and until Shares are in fact issued to such person
in connection with such Award.
17.2. WITHHOLDING.
The Company or any Affiliate shall have the authority and the right to deduct or withhold, or require a Participant to remit to the
Company or such Affiliate, an amount sufficient to satisfy federal, state, and local taxes (including the Participant’s FICA
obligation) required by law to be withheld with respect to any exercise, lapse of restriction or other taxable event arising as a
result of the Plan. The obligations of the Company under the Plan will be conditioned on such payment or arrangements and the
Company or such Affiliate will, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind
otherwise due to the Participant. Unless otherwise determined by the Committee at the time the Award is granted or thereafter, any
such withholding requirement may be satisfied, in whole or in part, by withholding from the Award Shares having a Fair Market Value
on the date of withholding equal to the amount required to be withheld in accordance with applicable tax requirements, all in
accordance with such procedures as the Committee approves (which procedures may permit withholding up to the maximum individual
statutory rate in the applicable jurisdiction as may be permitted under then-current accounting principles to qualify for equity
classification). All such elections shall be subject to any restrictions or limitations that the Committee, in its sole discretion,
deems appropriate.
17.3. SPECIAL PROVISIONS RELATED TO SECTION 409A OF THE CODE.
(a) It
is intended that the payments and benefits provided under the Plan and any Award shall either be exempt from the application of, or comply
with, the requirements of Section 409A of the Code. The Plan and all Award Certificates shall be construed in a manner that effects
such intent. Nevertheless, the tax treatment of the benefits provided under the Plan or any Award is not warranted or guaranteed. Neither
the Company, its Affiliates nor their respective directors, officers, employees or advisers (other than in his or her capacity as a Participant)
shall be held liable for any taxes, interest, penalties or other monetary amounts owed by any Participant or other taxpayer as a result
of the Plan or any Award.
(b) Notwithstanding
anything in the Plan or in any Award Certificate to the contrary, to the extent that any amount or benefit that would constitute non-exempt
“deferred compensation” for purposes of Section 409A of the Code (“Non-Exempt Deferred Compensation”) would
otherwise be payable or distributable, or a different form of payment (e.g., lump sum or installment) of such Non-Exempt Deferred Compensation
would be effected, under the Plan or any Award Certificate by reason of the occurrence of a Change in Control, or the Participant’s
Disability or separation from service, such Non- Exempt Deferred Compensation will not be payable or distributable to the Participant,
and/or such different form of payment will not be effected, by reason of such circumstance unless the circumstances giving rise to such
Change in Control, Disability or separation from service meet any description or definition of “change in control event”,
“disability” or “separation from service”, as the case may be, in Section 409A of the Code and applicable
regulations (without giving effect to any elective provisions that may be available under such definition). This provision does not affect
the dollar amount or prohibit the vesting of any Award upon a Change in Control, Disability or separation from service, however
defined. If this provision prevents the payment or distribution of any amount or benefit, or the application of a different form of payment
of any amount or benefit, such payment or distribution shall be made at the time and in the form that would have applied absent the non-409A-conforming
event.
(c) If
any one or more Awards granted under the Plan to a Participant could qualify for any separation pay exemption described in Treas. Reg.
Section 1.409A-1(b)(9), but such Awards in the aggregate exceed the dollar limit permitted for the separation pay exemptions, the
Company shall determine which Awards or portions thereof will be subject to such exemptions.
(d) Notwithstanding
anything in the Plan or in any Award Certificate to the contrary, if any amount or benefit that would constitute Non-Exempt Deferred
Compensation would otherwise be payable or distributable under this Plan or any Award Certificate by reason of a Participant’s
separation from service during a period in which the Participant is a Specified Employee, then, subject to any permissible
acceleration of payment by the Committee under Treas. Reg. Section 1.409A-3(j)(4)(ii) (domestic relations order),
(j)(4)(iii) (conflicts of interest), or (j)(4)(vi) (payment of employment taxes): (i) the amount of such Non-Exempt
Deferred Compensation that would otherwise be payable during the six-month period immediately following the Participant’s
separation from service will be accumulated through and paid or provided on the first day of the seventh month following the
Participant’s separation from service (or, if the Participant dies during such period, within 30 days after the
Participant’s death) (in either case, the “Required Delay Period”); and (ii) the normal payment or
distribution schedule for any remaining payments or distributions will resume at the end of the Required Delay Period.
(e) If,
pursuant to an Award, a Participant is entitled to a series of installment payments, such Participant’s right to the series of installment
payments shall be treated as a right to a series of separate payments and not to a single payment. For purposes of the preceding sentence,
the term “series of installment payments” has the meaning provided in Treas. Reg. Section 1.409A-2(b)(2)(iii) (or
any successor thereto).
(f) Whenever
an Award conditions a payment or benefit on the Participant’s execution and non- revocation of a release of claims, such
release must be executed and all revocation periods shall have expired within 60 days after the date of termination of the
Participant’s employment; failing which such payment or benefit shall be forfeited. If such payment or benefit is exempt from
Section 409A of the Code, the Company may elect to make or commence payment at any time during such 60-day period. If such
payment or benefit constitutes Non-Exempt Deferred Compensation, then, subject to subsection (d) above, (i) if such 60-day
period begins and ends in a single calendar year, the Company may make or commence payment at any time during such period at its
discretion, and (ii) if such 60-day period begins in one calendar year and ends in the next calendar year, the payment shall be
made or commence during the second such calendar year (or any later date specified for such payment under the applicable Award),
even if such signing and non-revocation of the release occur during the first such calendar year included within such 60-day period.
In other words, a Participant is not permitted to influence the calendar year of payment based on the timing of signing the
release.
(g) The
Company shall have the sole authority to make any accelerated distribution permissible under Treas. Reg. Section 1.409A-3(j)(4) to
Participants of deferred amounts, provided that such distribution(s) meets the requirements of Treas. Reg. Section 1.409A-3(j)(4).
17.4. UNFUNDED
STATUS OF AWARDS. The Plan is intended to be an “unfunded” plan for incentive and deferred compensation. With respect
to any payments not yet made to a Participant pursuant to an Award, nothing contained in the Plan or any Award Certificate shall give
the Participant any rights that are greater than those of a general creditor of the Company or any Affiliate. In its sole discretion,
the Committee may authorize the creation of grantor trusts or other arrangements to meet the obligations created under the Plan to deliver
Shares or payments in lieu of Shares or with respect to Awards. This Plan is not intended to be subject to ERISA.
17.5. RELATIONSHIP
TO OTHER BENEFITS. No payment under the Plan shall be taken into account in determining any benefits under any pension, retirement,
savings, profit sharing, group insurance, welfare or benefit plan of the Company or any Affiliate unless provided otherwise in such other
plan. Nothing contained in the Plan will prevent the Company from adopting other or additional compensation arrangements, subject to stockholder
approval if such approval is required; and such arrangements may be either generally applicable or applicable only in specific cases.
17.6. EXPENSES.
The expenses of administering the Plan shall be borne by the Company and its Affiliates.
17.7. TITLES
AND HEADINGS. The titles and headings of the Sections in the Plan are for convenience of reference only, and in the event of any conflict,
the text of the Plan, rather than such titles or headings, shall control.
17.8. GENDER
AND NUMBER. Except where otherwise indicated by the context, any masculine term used herein also shall include the feminine; the plural
shall include the singular and the singular shall include the plural.
17.9. FRACTIONAL
SHARES. No fractional Shares shall be issued and the Committee shall determine, in its discretion, whether cash shall be given in
lieu of fractional Shares or whether such fractional Shares shall be eliminated by rounding up or down.
17.10. GOVERNMENT AND OTHER
REGULATIONS.
(a) Notwithstanding
any other provision of the Plan, no Participant who acquires Shares pursuant to the Plan may, during any period of time that such
Participant is an affiliate of the Company (within the meaning of the rules and regulations of the Securities and Exchange
Commission under the 1933 Act), sell such Shares, unless such offer and sale is made (i) pursuant to an effective registration
statement under the 1933 Act, which is current and includes the Shares to be sold, or (ii) pursuant to an appropriate exemption
from the registration requirement of the 1933 Act, such as that set forth in Rule 144 promulgated under the 1933 Act.
(b) Notwithstanding
any other provision of the Plan, if at any time the Committee shall determine that the registration, listing or qualification of the Shares
covered by an Award upon any Exchange or under any foreign, federal, state or local law or practice, or the consent or approval of any
governmental regulatory body, is necessary or desirable as a condition of, or in connection with, the granting of such Award or the purchase
or receipt of Shares thereunder, no Shares may be purchased, delivered or received pursuant to such Award unless and until such registration,
listing, qualification, consent or approval shall have been effected or obtained free of any condition not acceptable to the Committee.
Any Participant receiving or purchasing Shares pursuant to an Award shall make such representations and agreements and furnish such information
as the Committee may request to assure compliance with the foregoing or any other applicable legal requirements. The Company shall not
be required to issue or deliver any certificate or certificates for Shares under the Plan prior to the Committee’s determination
that all related requirements have been fulfilled. The Company shall in no event be obligated to register any securities pursuant to the
1933 Act or applicable state or foreign law or to take any other action in order to cause the issuance and delivery of such certificates
to comply with any such law, regulation or requirement.
17.11. GOVERNING
LAW. To the extent not governed by federal law, the Plan and all Award Certificates shall be construed in accordance with and governed
by the laws of the State of Delaware.
17.12. SEVERABILITY.
In the event that any provision of this Plan is found to be invalid or otherwise unenforceable under any applicable law, such invalidity
or unenforceability will not be construed as rendering any other provisions contained herein as invalid or unenforceable, and all such
other provisions will be given full force and effect to the same extent as though the invalid or unenforceable provision was not contained
herein.
17.13. NO
LIMITATIONS ON RIGHTS OF COMPANY. The grant of any Award shall not in any way affect the right or power of the Company to make adjustments,
reclassification or changes in its capital or business structure or to merge, consolidate, dissolve, liquidate, sell or transfer all or
any part of its business or assets. The Plan shall not restrict the authority of the Company, for proper corporate purposes, to draft
or assume awards, other than under the Plan, to or with respect to any person. If the Committee so directs, the Company may issue or transfer
Shares to an Affiliate, for such lawful consideration as the Committee may specify, upon the condition or understanding that the Affiliate
will transfer such Shares to a Participant in accordance with the terms of an Award granted to such Participant and specified by the Committee
pursuant to the provisions of the Plan.
The foregoing
is hereby acknowledged as being the Checkpoint Therapeutics, Inc. Amended and Restated 2015 Incentive Plan, which was amended and
restated effective as of March 21, 2024, contingent on approval of the stockholders of the Company on May 13, 2024.
|
CHECKPOINT THERAPEUTICS, INC. |
|
|
|
By: |
James F. Oliviero |
|
|
|
|
Its: |
President & Chief Executive Officer |
v3.24.1.1.u2
Cover
|
May 13, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
May 13, 2024
|
Current Fiscal Year End Date |
--12-31
|
Entity File Number |
001-38128
|
Entity Registrant Name |
Checkpoint
Therapeutics, Inc.
|
Entity Central Index Key |
0001651407
|
Entity Tax Identification Number |
47-2568632
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
95
Sawyer Road
|
Entity Address, Address Line Two |
Suite
110
|
Entity Address, City or Town |
Waltham
|
Entity Address, State or Province |
MA
|
Entity Address, Postal Zip Code |
02453
|
City Area Code |
781
|
Local Phone Number |
652-4500
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, par value $0.0001 per share
|
Trading Symbol |
CKPT
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Checkpoint Therapeutics (NASDAQ:CKPT)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Checkpoint Therapeutics (NASDAQ:CKPT)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024